(Washington, DC – February 22, 2016) –  Galileo Analytics Co-Founder Anna McCollister-Slipp will speak an an upcoming FDA Center for Devices and Radiological Health (CDRH) workshop on regulatory considerations for providing genetic data to patients and medical professionals, which is scheduled for March 2.

The panel is part of a day-long workshop focused on seeking the perspective of patient advocates, entrepreneurs and medical professionals on issues the FDA needs to consider as the agency develops new policies about returning results of genetic tests and genome sequencing to patients.

McCollister-Slipp’s panel is focused specifically on the needs and issues related to the management of patients with chronic illness.

The workshop is aimed at addressing key policy questions involved in creating the Precision Medicine Initiative, which President Obama announced in January 2015. The will begin with remarks from Jo Handelsman, PhD, Associate Director for Science at the White House Office of Science and Technology Policy and Kathy Hudson, PhD, Deputy Director for Science, Outreach and Policy at the National Institutes of Health. Closing remarks will be provided by Jeffrey Shuren, MD, JD, the Director of CDRH.

More information about the workshop and McCollister-Slipp’s panel is available at the FDA Center for Devices and Radiological Health Website.



About Admin

Anna McCollister-Slipp is co-founder of Galileo Analytics, a Visual Data Exploration and advanced data analytics company focused on democratizing access to and understanding of complex health data. In addition, she is the Chief Advocate for Participatory Research at the Scripps Translational Science Institute, where she is charged with bringing the expertise of patients, caregivers and community physicians into the design of health research. Anna’s passion for innovation in health data research is rooted in her personal experiences living with type 1 diabetes. As an entrepreneur and advocate, she speaks frequently about the promise of digital health, the imperative for patient data access and the need for improved outcomes measures for chronic disease. Anna serves on a number of government and private committees and boards aimed at promoting innovative ways to better understand, manage and treat complex health conditions, such as diabetes.

%d bloggers like this: